Final Day of BIO International Convention Begins in Philadelphia

The 2019
BIO International Convention, the
world’s premier life sciences event, kicked off its fourth and final day
of programming today under the theme “It Starts With One.” This year’s
theme recognizes many of the “ones”– one partnership, one idea, one
question, one “a-ha” moment – that can lead to globally important
advancements in biotech.

The final day of Convention programming will include a Super Session
with Nature Biotechnology and Scientific American WORLDVIEW
on the main drivers of biotech innovation in markets around the world.
The day’s agenda will also include Start-up Stadium presentations and
educational sessions on topics such as personalized medicine in cancer
care, clinical trial design for rare disease, and the evolving landscape
of biotech venture capital, among other topics.

Thursday, June 6, Highlights Include:

• Super Session: Nature
  Biotechnology and Scientific American WORLDVIEW: Biotech Innovation in
  a Faster Future
  12:00–1:30 pm | 113ABC, Level 100
  This
  session will tackle the latest commercial, scientific and ethical
  issues facing innovation stakeholders today. Panel members will share
  their views of on the future of biotech innovation.
• Start-Up
  Stadium
  10:30 am–1:00 pm | Exhibitor Hall, 3971, Level
  200
  Designed to provide start-up-level companies with the
  opportunity to engage key members of the investment community and
  venture philanthropy groups. BIO attendees can watch these impressive
  companies pitch their products to a panel of investor judges.
• Clinical
  and Economic Value of Personalized Cancer Treatment
  9:00
  AM–10:15 AM | 116, Level 100
  This session will
  feature a discussion on the clinical utility and economic value of
  NGS-based diagnostic testing in cancer care. Panelists will highlight
  data sources and original research results that will provide clinical
  utility and health economic value evidence of genomic profiling
  technologies.

• Rare
  Finds: Innovative Clinical Trial Design for Rare and Orphan Diseases
  10:30
  AM–11:45 AM | 106AB, Level 100
  Attendees will hear from
  biotech companies who are addressing the challenges of rare disease
  trial design head-on, through innovative strategies for identifying
  potential enrollees, data gathering and even identifying new
  biomarkers to serve as clinical endpoints.

• The
  Evolving Landscape of Venture Capital
  10:30 AM–11:45
  AM | 107AB, Level 100
  This session will bring together
  traditional and corporate venture capitalists to share perspectives on
  the factors fueling further investment in human healthcare. Panelists
  will also share views of the current entrepreneurial scene and how it
  will change in 2019.

Follow the 2019 Convention @BIOConvention
and join the conversation @IAmBIOtech.

About BIO

BIO is the world's largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations. BIO members are involved in the research and development of
innovative healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO
International Convention, the world’s largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIOtechNOW is
BIO's blog chronicling “innovations transforming our world” and the BIO
Newsletter is the organization’s bi-weekly email newsletter. Subscribe
to the BIO Newsletter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005011/en/